Latest Radiofrequency ablation Stories
Thermedical, a privately held company currently developing a proprietary ablation therapy for the treatment of cancer, announced today that it has received a $3.6 million Competing Phase 2 Renewal Grant from the National Heart, Lung and Blood Institute. The three-year grant will fund continued development and testing of the company's Saline Enhanced Radiofrequency Ablation (SERF) system, which is designed for use in ablation treatment for ventricular tachycardia (VT). "The funding from the...
SUNNYVALE, Calif., Oct. 19 /PRNewswire/ -- BARRX Medical, Inc. today announced clinical trial results presented at the United European Gastroenterology Week (UEGW) in Vienna, Austria, October 18-22, 2008. In a plenary presentation entitled, "Stepwise circumferential and focal radiofrequency energy ablation of Barrett's esophagus with early neoplasia: First European Multi-centre trial" patients with the most advanced stages of Barrett's esophagus, dysplasia and early cancer, were staged with...
AUSTIN, Texas, Oct. 7 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has been selected as one of only a few sites in the nation to participate in an FDA-approved clinical trial for a new device to treat persistent atrial fibrillation. TCAI, an international treatment, training and research center specializing in heart rhythm disorders, is a partnership between St. David's Medical Center and Texas Cardiovascular Consultants. "This is just another...
U.S. scientists say they've discovered merging multiple computerized tomography images can aid probe positioning during radiofrequency ablation. The researchers at the Dartmouth-Hitchcock Medical Center in Lebanon, N.H., said radiofrequency ablation is used to destroy biological tissue for medical treatments of various lesions. "During radiofrequency ablation the probe often needs to be repositioned in order to effectively treat an entire lesion," said Dr. John Gemery, author of the study,...
By Howard, J Harrison Tzeng, Ching-Wei D; Smith, J Kevin; Eckhoff, Devon E; Bynon, J Steve; Wang, Thomas; Arnoletti, J Pablo; Heslin, Martin J Surgical resection of primary or metastatic tumors of the liver offers patients the best long-term survival. Liver resections may not be appropriate in patients with bilobar metastases, liver dysfunction, or severe comorbidities. Radiofrequency ablation (RFA) is a technique used to destroy unresectable hepatic tumors through thermocoagulation. We...
CELSION CORPORATION (NASDAQ: CLSN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox(R) used in combination with Radio Frequency Ablation (RFA) for the treatment of patients with primary and metastatic liver cancer will be presented at a Poster Presentation session at the International Liver Cancer Association (ILCA) Annual Conference in Chicago, IL, from September 5-7, 2008. This annual conference is recognized as a premier...
St. Jude Medical, Inc. (NYSE:STJ) has received European CE Mark approval and U.S. Food and Drug Administration (FDA) clearance for the Epicor(TM) LP Cardiac Ablation System, a second generation technology that uses HIFU (high intensity focused ultrasound) to surgically ablate cardiac tissue to disrupt abnormal electrical impulses in the heart. The first patient to undergo treatment with the Epicor LP System was a 73-year-old male with coronary artery disease and atrial fibrillation (AF)....
AUSTIN, Texas, Aug. 13 /PRNewswire/ -- This week, doctors at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to implement the CoHesion(TM) 3D Visualization Module -- an enhancement to the state-of-the art Hansen Robotic system used to treat cardiac arrhythmias. With the visualization module, patients undergoing the ablation treatment for heart arrhythmias are exposed to about 30 percent less radiation than without the new technology,...
A study of patients with kidney cancer has shown that radiofrequency ablation, a minimally invasive, kidney-sparing procedure, can be a successful treatment option for patients whose cancer has not spread beyond the kidney, report researchers at Wake Forest Baptist Medical Center. Results from the three year study, which evaluated 22 patients who received the treatment, are published in the July issue of the American Journal of Roentgenology. The treatment uses computed tomography to guide...
AngioDynamics (NASDAQ:ANGO) announced today results from its RAPTURE study, which was conducted to identify the feasibility, efficacy and safety of percutaneous radiofrequency ablation (RFA) of malignant lung tumors. Published in The Lancet Oncology July 2008 issue, the results show a high proportion of sustained, complete tumor response after treatment with RFA. This prospective, intention-to-treat clinical trial enrolled 106 patients with 183 lung tumors that were 3.5 cm in diameter or...
